Targeting angiogenic pathways involving tumor-stromal interaction to treat advanced human prostate cancer

Cancer and Metastasis Reviews

Volumn 17, Issue 4, 1998, Pages 307-315

  Sokoloff, Mitchell H ^a   Chung, Leland W K ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Anti angiogenesis; Intermittent androgen suppression; Prostate cancer; Stromal epithelial interactions

Indexed keywords

ANDROGEN; ANGIOGENESIS INHIBITOR; ANTIINFECTIVE AGENT; GROWTH FACTOR;

ANGIOGENESIS; CANCER CELL; CANCER GROWTH; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HORMONAL THERAPY; HUMAN; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STROMA CELL;

EID: 0032799005     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006170612253     Document Type: Review

References (64)

1. Raghavan D, Koczwara B, Javle M: Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Canc 33: 566-574, 1997
2. Bane RL, Torti FM. Endocrine therapy for prostate cancer. Canc Treat Res 94: 69-87, 1998
3. Gleave ME, Hsieh JT, Gao C, von Eschenbach AC, Chung LWK: Acceleration of human prostate cancer growth in vivo by prostate and bone fibroblasts. Canc Res 51: 3753-3761, 1991
4. Chung LWK: Implications of stromal-epithelial interaction in human prostate cancer growth, progression, and differentiation. Sem Canc Biol 4: 183-192, 1993
5. Chung LWK: Stromal-epithelial interactions dictate prostate cancer androgen independent metastatic progression. Canc Det Prev 22 (Supplement 1): 57-58, 1998
6. Ellis LM, Fidler IJ: Angiogenesis and Metastasis. Eur J Canc 32A: 2451-2460, 1996
7. Weinstat-Saslow D, Steeg P: Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J 8: 401-407, 1994
8. Polverini PJ: How the extracellular matrix and macrophages contribute to angiogenesis-dependent diseases. Eur J Canc 32A: 2430-2437, 1996
9. Folkinan J: Clinical applications of research on angiogenesis. New Engl J Med 333: 1757-1763, 1995
10. Boehm T, Folkman J, Bowder T, O'Reilly MS: Anti-angiogenic therapy of experimental cancer does not induce drug resistance. Nature 390: 404-407, 1997
11. 3 expression by squalamine obliterates advanced human prostate cancer. Submitted
12. Sills AK, Williams JI, Tyler BM, Epstein DS, Sipos EP, Davis JD, McLane MP, Pitchford S, Cheshire K, Gannon FH, Kinney WA, Chao TL, Donowitz M, Laterra J, Zasloff M, Brem H: Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Canc Res 58: 2784-2792, 1998
13. Teicher BA, Williams JI, Takeuchi H, Ara G, Herbst RS, Buxton D: Potential of the aminosterol squalamine in combination therapy in rat mammary carcinoma and murine Lewis lung carcinoma. Anticancer Res 18: 2567-2573, 1998
14. Brooks PC: Role of integrins in angiogenesis. Eur J Canc 32A: 2423-2429, 1996
15. Bussolino F, Albini A, Camussi G, Presta M, Viglietto G, Ziche M, Persico G: Role of soluble mediators in angiogenesis. Eur J Canc 32A: 2401-2412, 1996
16. Ausprunk DH, Folkrnan J: Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14: 53-65, 1977
17. Paku S, Paweletz N: First steps in tumor-related angiogenesis. Lab Invest 65: 334-346, 1991
18. Folkman J, Cotran R: Relation of vascular proliferation to tumor growth. Internat Rev Exp Pathol 16: 207-248, 1976
19. Folkman J, Klagsburn M: Angiogenic factors. Science 235: 442-447, 1987
20. Pepper MS: Manipulating angiogensis: from basic science to the bedside. Arterioscle Throm Vasc Biol 17: 605-619, 1997
21. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, Kuwano M: Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cel Biochem 17: 4015-4023, 1997
22. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrine Rev 13: 18-32, 1992
23. Ferrara N: Vascular endothelial growth factor. Eur J Canc 32A: 2413-2422, 1996
24. Claffet KP, Robinson GS: Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Canc Metast Rev 15: 165-1996
25. Jackson MW, Bentel JM, Tillet WD: Vascular endothelial growth factor expression in prostate cancer and benign prostatic hyperplasia. J Urol 157: 2323-2328, 1997
26. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL: Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 157: 2329-2333, 1997
27. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL: Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 51: 161-167, 1998
28. Weidner N, Carroll PR, Flax J, Blumenthal W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate cancer. Am J Pathol 143: 401-409, 1993
29. Joseph IBJK, Nelson JB, Denmeade SR, Isaacs JT: Androgens regfulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Canc Res 3: 2507-2511, 1997
30. Joseph IBJK, Isaacs JT: Potentiation of anti-angiogenic ability of Linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Canc Res 57: 1054-1057, 1997
31. Varner JA, Cheresh DA: Integrins and cancer. Curr Opin Cell Biol 8: 724-730, 1996
32. Thalmann GN, Anezmis PE, Chang S-M, Zhau HE, Kim E, Nopwood VL, Pathak S, von Eschenbach AC, Chung LWK: Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Canc Res 54: 2577-2581, 1994
33. Thalmann GN, Anezinis PE, Chung LWK, Devoll R, Farach-Carson C: Experimental approaches to skeletal metastasis of human prostate cancer. In: Raghavan D, Scher HI, Leibel SA, Lange P (eds) Principles and Practice of Genitourinary Oncology. Lippincott-Raven, Philadelphia, 1996, pp 409-416.
34. Cherish DA: Death to a blood vessel, death to a tumor. Nature Medicine 4: 395-396, 1998
35. Brooks PC, Montgomery AMP, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA: Integrin alpha-v beta-3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164, 1994
36. Brooks PC, Clark RAF, Cheresh DA: Requirement of vascular integrin alpha-v beta-3 for angiogenesis. Science 264: 569-571, 1994
37. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA: Predictors of pathologic stage in prostate cancer: the role of neovascualrity. Cancer 73: 678-672, 1994
38. Silberman MA, Partin AW, Veltri RW, Epstein JI: Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 79: 772-779, 1997
39. Woessner RD, Wright PS, Loudy DE, Wallace CD, Montgomery LR, Nestok BR: Microautoradiographic quantitation of vascular endothelial growth actor mRNA levels in human prostate specimens containing normal and neoplastic epithelium. Exp Mol Pathol 65: 37-52, 1998
40. Brawer MK: Neovascularity in human prostate cancer. In: Belldegrun A, Kirby RS, Oliver T (eds) New Perspectives in Prostate Cancer. Isis, Oxford, 1998, pp 71-76
41. Paulson DF: Treatment of localized cancer of the prostate. In: Lepor H, Lawson RK (eds) Prostate Diseases. WB Saunders, Philadelphia, 1993, pp 368-377
42. Schellhammer PF: Radical prostatectomy: patterns of local failure and survival. Urology 31: 191-7, 1988
43. Lerner SP, Seale-Hawkins C, Carlton CE, Scardino FT: The risk of dying of prostate cancer in patients with clinically localized disease. J Urol 146: 1040-50, 1991
44. Catalona WJ, Dresner SM: Nerve-sparing radical prostatectomy: extraprostatic tumor extension and preservation of erectile function. J Urol 134: 1149-55, 1985
45. Lu-Yao G, McLarran D, Wasson J, Wennberg JE: An assessment of radical prostatectomy. J Am Med Ass 269: 2633-36, 1993
46. Scher HI, Chung LWK: Bone metastasis: improving the therapeutic index. Sem Oncol 21: 630-656, 1994
47. Shibata A, MA J, Whittemore AS: Prostate cancer incidence and mortality in the United States and United Kingdom. J Nat Canc Inst 90: 1230-1231, 1998
48. Granfors T, Modig H, Danber JE, Tomic R: Combined orchiectomy and radation therapy for nonmetastatic prostate cancer. J Urol 159: 2030-2034, 1998
49. Dameron KM, Volpert OV, Tainsky MA, Bouch N: Control of angiogenesis in fibroblasts by p53 regulation of thrmobospondin-1. Science 265: 1582-1584, 1994
50. Ruley HE: p53 and response to chemotherapy and radiotherapy. Imp Adv Oncol, 1996, pp 37-56
51. Mukhopadhyay D, Nagy JA, Manseau EJ, Dvorak HF: Vascular permeability factor/vascular endothelial derived growth factor mediated signaling in mouse messentary vascular endothelium. Canc Res 58: 1278-1284, 1998
52. Folkinan J: Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence (editorial). Endocrinol 139: 441-442, 1998
53. Frank-Lissbrant I, Haggstrom S, Damber J-E, Bergh A: Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinol 139: 451-456, 1998
54. Haggstrom S, Wikstrom P, Bergh A, Damber J-E: Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration. Prostate 36: 71-79, 1998
55. Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, Benjamin L, Yuan F, Keshet E: Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Nat Ac Science 95: 10820-10825, 1998
56. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD: Intermittent androgen suppression delays progression to androgen-independet regulation of prostate specific antigen gene in the LNCaP prostate tumor model. J Ster Biochem Mol Biol 58: 139-146, 1996
57. Theyer G, Hamilton G: Current status of intermittent androgen suppression in the treatment of prostate cancer. Urol 52: 353-359, 1998
58. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K: Intermittent androgen suppression in the treatment of prostate cancer. Urol 47: 956-961, 1995
59. Higano CS, Ellis W, Russel K, Lange PH: Intermittent androgen suppression with leuprolide and flutamide for prostate cancer. Urol 48: 800-804, 1996
60. Zhau HE, Chang S-M, Chen B-Q, Wang Y-L, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LWK: Androgen-repressed phenotype in human prostate cancer. Proc Nat Ac Science 93: 15152-15157, 1996
61. Fajardo LF, Berthrong M: Vascular lesions following radiation. Path Ann 23: 297-300, 1988
62. Fajardo LF: Morphology of radiation effects on normal tissues. In: Perez CA, Brady LW (eds) Princ Prac Rad Oncol. Lippincott, Philadelphia, 1997, pp 143-154
63. Hudes OR, Natha F, Khater C, Haas N, Cornbfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Rosss E, Roethke S, McAleer C: Phase II trial of 96-hour paclitaxel plus oral estramustine phospate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15: 3156-63, 1997
64. Pienta KJ, Smith DC: Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer. Sem Oncol 24 (Supplement 5): 72-75, 1997